In a trial of TAVR in patients with a small aortic annulus, a self-expanding valve was noninferior to a balloon-expandable valve for clinical outcomes and was superior for bioprosthetic-valve dysfunction through 12 months.
The New England Journal of Medicine: Search Results in Cardiology
